Table 1 Patient characteristics

From: S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study

 

Total ( n =73)

Patients given RD ( n =52)

Characteristic

N

%

N

%

Age (years), median (range)

53 (29–73)

53 (29–73)

Men

56

76.7

38

73.1

Tumour size (cm), median (range)

4.5 (2–18)

4.0 (2–11.5)

Location of primary tumour

    

 Upper 1/3 of stomach

11

15.1

6

11.5

 Middle 1/3 of stomach

10

13.7

8

15.4

 Lower 1/3 of stomach

39

53.4

27

51.9

2 sites involved

13

17.8

11

21.2

Positive LNs, median (range)

9 (1–45)

11.5 (1–45)

LNs resected, median (range)

31 (8–79)

34 (14–79)

LN ratio, median (range)

0.32 (0.05–0.90)

0.30 (0.05–0.90)

Extent of dissection

    

 D1

20

27.4

10

19.2

 D2

53

72.6

42

80.8

Lauren type

    

 Intestinal type

12

16.4

8

15.4

 Diffuse type

27

37.0

20

38.5

 Mixed type

20

27.4

14

26.9

 Undetermined

14

19.2

10

19.2

Tumour differentiation

    

 Good

1

1.4

1

1.9

 Moderate

9

12.4

7

13.4

 Poor

63

86.2

44

84.7

Lymphatic/vascular invasion

    

 Present

40

54.8

30

57.7

 Absent

33

45.2

22

42.3

Perineural invasion

    

 Present

35

47.9

32

61.5

 Absent

38

52.1

20

38.5

Stage (AJCC Seventh)

    

 IIa

2

2.7

0

0

 IIb

6

8.2

3

5.8

 IIIa

15

20.6

10

19.2

 IIIb

35

47.9

25

48.1

 IIIc

15

20.6

14

26.9

Stage (AJCC Sixth)

    

 Ib

2

2.7

0

0

 II

17

23.3

10

19.2

 IIIa

31

42.5

22

42.3

 IIIb

7

9.6

6

11.5

 IV

16

21.9

14

26.9

  1. Abbreviations: AJCC=American Joint Committee on Cancer; LN=lymph node; RD=recommended dose.